profit from every $100 of sales.
$0$100
Valneva
$5.92+0.85% today
-33.4% in 1 year
1-year low $4.781-year high $11.99
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Valneva sold, what it kept, and what it did with the cash.
Sales went from €361 million in 2022 to €175 million in 2025, with -€115 million of profit last year.
SalesProfit
Valneva vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Valneva | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Valneva's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 361 | 154 | 170 | 175 | |
| 37 | 53 | 71 | 68 | |
| -113 | -82 | -78 | -82 | |
| -105 | -58 | 32 | -50 | |
| -143 | -101 | -12 | -115 | |
| -2.48 | -1.46 | -0.16 | -1.36 | |
| 10.2% | 34.4% | 41.9% | 38.7% | |
| -31.4% | -53.4% | -45.9% | -46.7% | |
| -39.7% | -66.0% | -7.2% | -66.0% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 621 | 460 | 500 | 399 |
| Cash | 287 | 126 | 168 | 110 |
| Total debt | 152 | 209 | 216 | 207 |
| Total liabilities | 402 | 332 | 319 | 293 |
| 220 | 128 | 181 | 106 | |
| 58 | 69 | 73 | 84 | |
| -26.7% | -17.6% | 2.5% | -18.2% | |
| -65.2% | -79.1% | -6.8% | -108.5% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -245 | -203 | -67 | -53 | |
| 29 | 14 | 16 | 4 | |
| -275 | -217 | -84 | -57 | |
| Dividends paid | 0 | 0 | 0 | 0 |
| – | 0 | – | – | |
| -9 | 5 | 8 | 10 |
Valuation
- –
- –
- –
- 4.5×
- 2.9×
- –
- –
- -11.3%
- -22.7%
- 0.0%
Profitability
- 38.7%
- -46.7%
- -66.0%
- -39.0%
- -27.0%
- -26.8%
- -74.5%
- -28.9%
- -28.8%
- 48.8%
Growth
- −21.5%
- –
- +31.4%
- –
- +14.6%
Financial health
- –
- 1.95
- 52.0%
- -2.1×
- 2.38
- 1.85
- 0.44
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 16%of 958
Bottom 6%of 888
Bottom 4%of 889
Bottom 9%of 987
What analysts expect
- Average price target
- $11.00
- Range
- $11.00 – $11.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.42 | -0.21 | −100.0% |
| Mar 16, 2026 | -0.68 | -0.17 | −293.1% |
| Nov 20, 2025 | -0.61 | -0.30 | −103.3% |
| Aug 12, 2025 | -0.16 | -0.27 | +40.7% |
| May 7, 2025 | -0.13 | -0.31 | +58.1% |
| Mar 20, 2025 | -0.54 | -0.22 | −145.5% |
| Nov 7, 2024 | -0.15 | -0.30 | +50.0% |
| Aug 13, 2024 | -0.37 | -0.39 | +5.1% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
17No pass
Benjamin Graham
22No pass
Philip Fisher
26No pass
Peter Lynch
10No pass
Joel Greenblatt
0No pass
Charlie Munger
17No pass
Terry Smith
19No pass
Questions about Valneva
Is Valneva a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Valneva AI analysis
What does Valneva do?
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. It is in Biotechnology.
Does Valneva pay a dividend?
No. Valneva does not pay a dividend at the moment.
Is Valneva stock halal?
No. Valneva does not pass our halal screen: its debt is 41% of its market value, at or above the 33% limit. How we check
How has Valneva stock done over the past year?
Down 33.4% over the past twelve months, to $5.92. It traded between $4.78 and $11.99 and is 50.6% below its high.
Who are Valneva's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Valneva's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.